← Back to headlines
Eli Lilly Reports Strong Q1 2026 Earnings Driven by Mounjaro and Zepbound
Pharmaceutical company Eli Lilly announced strong financial results for the first quarter of 2026, with significant growth attributed to the performance of its key drugs, Mounjaro and Zepbound.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Fed Chair Warsh Warns of Rate Hikes if U.S. Inflation Persists at Jackson Hole
31m ago
Trump Administration Proposes Plan for Farmers to Process Their Own Meat
35m ago
Rubrik Shares Fall After Disappointing Second-Quarter Earnings and Weak Guidance
42m ago
Marvell Shares Drop Despite Strong Earnings and Data Center Growth Forecast
54m ago